Abstract
Cannabinoids are signalling molecules which elicit their vascular effects mainly via G protein-coupled CB1 receptors and transient receptor potential (TRP) channels (chiefly vanilloid TRPV1 receptors). Cannabinoids can act at prejunctional CB1 receptors to inhibit perivascular sympathetic neurotransmission. The effects of cannabinoids on perivascular capsaicin-sensitive sensory nerves are more complex. Certain cannabinoids can activate sensory nerves through actions on TRPV1 receptors and other TRP channels, which leads to sensory neurotransmitter release (mainly calcitonin generelated peptide) and vasorelaxation. However, activation of TRP/TRPV1 channels can also lead to desensitization and loss of sensory nerve activity. Concentration and time of exposure may be critical in determining which of these opposite effects of cannabinoids prevails. In addition, there is evidence for the expression of CB1 receptors on perivascular capsaicinsensitive sensory nerves, coupled to inhibition of neurotransmitter release. There is evidence that the archetypal cannabinoid anandamide is released as a neurotransmitter in the central nervous system, and from sensory ganglia, but a release of cannabinoids from perivascular nerves has yet to be clearly demonstrated. Hence, with regard to perivascular nerves, cannabinoids appear to act principally as prejunctional modulators of neurotransmission. The diverse prejunctional effects of cannabinoids may be novel targets for therapies designed to treat vascular disease.
Keywords: Anandamide, autonomic nervous system, cannabinoids, peripheral nervous system, sensory nerves, sympathetic nerves, vanilloids
Current Vascular Pharmacology
Title: Cannabinoid Modulation of Perivascular Sympathetic and Sensory Neurotransmission
Volume: 7 Issue: 1
Author(s): Vera Ralevic and David A. Kendall
Affiliation:
Keywords: Anandamide, autonomic nervous system, cannabinoids, peripheral nervous system, sensory nerves, sympathetic nerves, vanilloids
Abstract: Cannabinoids are signalling molecules which elicit their vascular effects mainly via G protein-coupled CB1 receptors and transient receptor potential (TRP) channels (chiefly vanilloid TRPV1 receptors). Cannabinoids can act at prejunctional CB1 receptors to inhibit perivascular sympathetic neurotransmission. The effects of cannabinoids on perivascular capsaicin-sensitive sensory nerves are more complex. Certain cannabinoids can activate sensory nerves through actions on TRPV1 receptors and other TRP channels, which leads to sensory neurotransmitter release (mainly calcitonin generelated peptide) and vasorelaxation. However, activation of TRP/TRPV1 channels can also lead to desensitization and loss of sensory nerve activity. Concentration and time of exposure may be critical in determining which of these opposite effects of cannabinoids prevails. In addition, there is evidence for the expression of CB1 receptors on perivascular capsaicinsensitive sensory nerves, coupled to inhibition of neurotransmitter release. There is evidence that the archetypal cannabinoid anandamide is released as a neurotransmitter in the central nervous system, and from sensory ganglia, but a release of cannabinoids from perivascular nerves has yet to be clearly demonstrated. Hence, with regard to perivascular nerves, cannabinoids appear to act principally as prejunctional modulators of neurotransmission. The diverse prejunctional effects of cannabinoids may be novel targets for therapies designed to treat vascular disease.
Export Options
About this article
Cite this article as:
Ralevic Vera and Kendall A. David, Cannabinoid Modulation of Perivascular Sympathetic and Sensory Neurotransmission, Current Vascular Pharmacology 2009; 7 (1) . https://dx.doi.org/10.2174/157016109787354114
DOI https://dx.doi.org/10.2174/157016109787354114 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
"New Frontiers in Cardiovascular and Hematologic Disease Treatment: Exploring and Applying Natural Drug Targets"
Cardiovascular and hematologic diseases are among the most pressing global health challenges, placing a heavy burden on public health systems worldwide. As research progresses, novel therapeutic targets continue to be identified, offering new possibilities for treating these complex conditions. However, despite advancements in current therapies, more integrated research approaches are ...read more
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Clinical Applications of (-), (+) and (±)-Z-Bisdehydrodoisynolic Acids in Metabolic Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) A Comment on Pluripotent Stem Cells in Next-Generation Biomedical Theranostics
Current Molecular Medicine Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery Is Mania the Hypertension of the Mood? Discussion of A Hypothesis
Current Neuropharmacology Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
CNS & Neurological Disorders - Drug Targets Pharmacological Management of Type 2 Diabetes Mellitus: An Update
Current Diabetes Reviews Targeting Epigenetic Modifiers: Promising Strategies for Cancer Therapy and Beyond
Current Drug Therapy Vascular Dysfunction in Hypertensive Disorders
Current Hypertension Reviews Basic and Clinical Aspects of Gene Therapy for Retinopathy Induced by Diabetes
Current Gene Therapy Insight into Molecular and Functional Diversity of Tachykinins and their Receptors
Protein & Peptide Letters Quantitative Electroencephalogram Analysis in Parkinson’s Disease
Neuroscience and Biomedical Engineering (Discontinued) Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Update on Alzheimer’s Disease Therapeutics
Reviews on Recent Clinical Trials Natural Non-Trasgenic Animal Models for Research in Alzheimers Disease
Current Alzheimer Research In Silico Studies towards Enhancing the Anticancer Activity of Phytochemical Phloretin Against Cancer Drug Targets
Current Drug Therapy Polycystic Ovary Syndrome in Adolescents
Current Women`s Health Reviews Editorial (Thematic Issue: Antiplatelet Treatment in Cardiovascular Disease: New Insights)
Current Pharmaceutical Design Inhibition of Early Upstream Events in Prodromal Alzheimer’s Disease by Use of Targeted Antioxidants
Current Aging Science Emerging Role of Complement in Ocular Diseases
Current Immunology Reviews (Discontinued) Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research